Genpharmasec Ltd Share Price Today - Genpharmasec Ltd Stock Price Live NSE/BSE

Genpharmasec Ltd

NSE: BSE: 531592

₹1.11

(-0.89%)

Thu, 12 Mar 2026, 03:02 am

MTF 5xInvest in Genpharmasec Ltd with 5x Leverage Buy with MTF

Market Cap620.17M

PE Ratio0

Dividend0

Process Industries

Chemicals: Specialty

24.5K

Genpharmasec Share Price Live Chart

1 Day

0 (0%)

No Result Found

Summary

Market Cap
61.46
Net Profit
1.23
P/B
1.60
Sector P/E
39.67
P/E
94.50
EV/EBITDA
33.34
Debt/Equity (Industry)
0.65
Interest Cover (Industry)
4.79
ROCE (Industry)
18.39
RONW (Industry)
17.80
ROE
1.85
ROCE
3.28
Debt/Equity
0.07
EPS (TTM)
0
Dividend Yield
0
Book Value
1.19
Interest Cover
5.18

Analysis

all

Pros

Generic Pharmasec is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Generic Pharmasec is profitable, therefore cash runway is not a concern.
Generic Pharmasec is profitable, therefore cash runway is not a concern.
Generic Pharmasec has no debt, it does not need to be covered by operating cash flow.
Generic Pharmasec has no debt, it does not need to be covered by short term assets.

Cons

Unable to evaluate Generic Pharmasec's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
Unable to evaluate Generic Pharmasec's dividend against the top 25% market benchmark as the company has not reported any payouts.
The average tenure for the Generic Pharmasec board of directors is less than 3 years, this suggests a new board.
Generic Pharmasec is not covered by any analysts.
Generic Pharmasec has significant price volatility in the past 3 months.

Financials

Ratios

Shareholders	DEC 2025	SEPT 2025	JUN 2025	MAR 2025	DEC 2024
Promoters	29.98	29.98	29.98	29.98	29.98
FII	0	0	0	0	0
DII	0	0	0	0	0
Public	70.02	70.02	70.02	70.02	70.02
Government	0	0	0	0	0

Technical Analysis

RSI

39.08

MACD

-0.04

50 DMA

1.24

200 DMA

1.69

Support and Resistance

Type	R3	R2	R1	PP	S1	S2	S3
Classic	2.14	1.67	1.43	1.20	0.96	0.73	0.26
Fibonacci	1.67	1.49	1.38	1.20	1.02	0.91	0.73
Camarilla	1.31	1.27	1.22	1.20	1.14	1.09	1.05

Pivots Level: Classic

+0.94

2.14

+0.47

1.67

+0.22

1.43

1.20

Pivot Point

LTP: 1.11

-0.25

0.96

-0.47

0.73

-0.94

0.26

Moving Average

SMAEMA

Period

Value

10-EMA
1.16
20-EMA
1.19
30-EMA
1.21
50-EMA
1.26
100-EMA
1.39
200-EMA
1.64

Announcement Date	Purpose	Action	Ex Date
09 Feb 2026	board-meetings	Quarterly Results
06 Nov 2025	board-meetings	Quarterly Results, Half Yearly Results
02 Sept 2025	agm
27 Jun 2024	agm
03 Jan 2024	rights	1:1 Rights Issue of Equity Shares	09 Jan 2024
09 Dec 2023	rights	Right Issue of Equity Shares	09 Jan 2024
31 Aug 2023	agm
08 May 2023	egm
21 Sept 2022	agm
06 Sept 2021	agm

Genpharmasec Ltd

Honasa Consumer Ltd

Redington Ltd

Aegis Logistics Ltd

Premier Energies Ltd

Adani Enterprises Ltd

Genpharmasec Ltd About

Genpharmasec is dealing primarily in pharmaceutical activities / services and trading in equity shares.

Industry

Trading

Founded

1992

Headquarters

CEO

Employees

Contact

Website

http://www.genpharmasec.com

info@genpharmasec.com; compliance@genpharmasec.com

Phone

Location

Office 104 & 105 1st Flr, Gundecha Indl Kandivali (East), Mumbai, Maharashtra, 400101

Year	History
2011	Registered Office of the Company has been shifted to 23, Sarvopari Mall, Opp. Utsav Party Plot, Sola Road, Ahmedabad - 380063.
2014	Company has shifted its registered office from 23, Sarvopari Mall, Opp. Utsav Party Plot, Sola Road, Ahmedabad - 380063 to GF-64, Block I, Titanium City Center, Nr. Sachin Tower, 100 Ft Road, Satellite, Ahmedabad - 380015.
2019	The Company has split its face value from Rs. 10/- to Rs. 1/- Company name has changed to Generic Pharmasec Ltd. from Adi Rasayan Ltd.
2023	Company name has changed to Genpharmasec Ltd. from Generic Pharmasec Ltd.
2024	The company issued rights shares of Rs. 1 in the ratio of 1:1 at a premium of Rs. 0.75 per share.

Client Name	Order Side	QTY	Avg Price	Date
DIVYA DEVEN PATHAK	Sell	3500000	2.95	30 Dec 2024
MULTIPLIER SHARE & STOCK ADVISORS PRIVATE LIMITED	Sell	2857581	3.31	04 Sept 2024
MULTIPLIER SHARE & STOCK ADVISORS PRIVATE LIMITED	Buy	3057693	3.18	03 Sept 2024
MULTIPLIER SHARE & STOCK ADVISORS PRIVATE LIMITED	Sell	931149	3.27	03 Sept 2024
ISHAAN TRADEFIN LLP	Sell	4500000	3.87	30 Aug 2024
ISHAAN TRADEFIN LLP	Buy	4500000	3.71	30 Aug 2024
MANSI SHARE & STOCK ADVISORS PRIVATE LIMITED	Buy	3400003	3.78	30 Aug 2024
STALLION WEALTH MANAGEMENT LLP	Buy	6050000	3.36	27 Aug 2024
ISHAAN TRADEFIN LLP	Buy	4000000	3.22	27 Aug 2024
ISHAAN TRADEFIN LLP	Sell	4000000	3.36	27 Aug 2024

Genpharmasec Ltd News

Genpharmasec Q3FY26 Results: Revenue Surges 332%

Genpharmasec Limited reported strong standalone revenue growth of 332% YoY to Rs. 3,600.83 lakhs in Q3FY26, though consolidated operations showed mixed performance with subsidiary integration challenges.

09 Feb 2026

co actions results

Genpharmasec Limited Resubmits Clear Copy of Q2 FY2026 Financial Results

Genpharmasec Limited resubmitted clear copies of its financial results for the quarter and half year ended September 30, 2025, following BSE's request due to unclear figures in the previously submitted PDF. The company's standalone results showed total income of Rs 3,639.16 lakhs for the half year, with profit before tax of Rs 308.65 lakhs for the quarter. The consolidated results included subsidiaries Clinigenome India Private Limited (99.99% stake), Genpharmasec Middle East DMCC (52% stake), and Derren Healthcare Private Limited (70% stake). The financial results were reviewed by the Audit Committee and approved by the Board of Directors on November 6, 2025. The auditor's review found no material misstatements in the financial statements prepared in accordance with Indian Accounting Standards.

11 Nov 2025

earnings

Genpharmasec Limited Reports No Deviation in Rights Issue Fund Utilization

Genpharmasec Limited confirmed no deviation or variation in the use of proceeds from its Rights Issue for the quarter ended September 30, 2025. The company utilized funds as originally planned across four key objectives: Rs. 1443.58 lakhs to acquire equity shares from shareholders of Derren Healthcare Private Limited to make it a subsidiary, Rs. 289.00 lakhs out of allocated Rs. 588.00 lakhs to repay term loans, Rs. 1643.86 lakhs out of Rs. 1650.00 lakhs for working capital purposes, and Rs. 25.00 lakhs to meet issue expenses. The statement was reviewed by the Audit Committee and submitted to BSE as per SEBI regulations.

06 Nov 2025

corporate action

Genpharmasec Limited Reports Quarterly Financial Results for September 2025

Genpharmasec Limited's Board of Directors approved unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025. The company operates primarily in one business segment and has three subsidiaries: Clinigenome India Private Limited (99.99% stake), Genpharmasec Middle East DMCC (52.00% stake), and Derren Healthcare Private Limited (70.00% stake). The board meeting was held on November 6, 2025, commencing at 5:30 p.m. and concluding at 7:25 p.m. The financial statements were prepared in accordance with Indian Accounting Standards and reviewed by auditors Bilimoria Mehta & Co.

06 Nov 2025

earnings

Genpharmasec Limited Reports Strong Q1 FY26 Results with 155% Revenue Growth

Genpharmasec Limited approved its unaudited standalone and consolidated financial results for the quarter ended June 30, 2025. On a standalone basis, the company reported revenue from operations of Rs 1,211.32 lakhs compared to Rs 530.29 lakhs in the same quarter last year, representing significant growth. Profit for the period increased to Rs 155.92 lakhs from Rs 58.87 lakhs year-over-year. On a consolidated basis, revenue from operations reached Rs 1,204.32 lakhs versus Rs 519.50 lakhs in the previous year quarter, with consolidated profit of Rs 121.52 lakhs compared to Rs 28.68 lakhs. The company operates primarily in pharmaceuticals and laboratory testing segments through its subsidiaries Clinigenome India Private Limited and Genpharmasec Middle East DMCC. Basic earnings per share improved to Rs 0.03 on standalone basis and Rs 0.02 on consolidated basis. The results were reviewed by the audit committee and approved by the board on August 7, 2025.

07 Aug 2025

earnings

Open Your Free Demat Account Now!

Step into a world of zero fees and limitless opportunities!

Version -5.76

Stocks:

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Explore

Calculators

Popular Calculators

Group Stocks

Others:

NSE BSE CDSL NSDL SEBI MCX MSEI NCDEX NSE IFSC INDIA INX Account Closure Form DP Investor Charter Broker Investor Charter

Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800